- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Sibel Blau Discusses Technology Challenges and Data Sharing
The electronic medical record (EMR) can be burdensome but having a good value-based care team collecting data can help, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
The electronic medical record (EMR) can be burdensome but having a good value-based care team collecting data can help, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
Transcript
What have been some of the challenges you face with technology and data sharing?
There is a need to put as much structured data as possible, predetermined by workers on creating the EMR and working with them on how we need that information to be put in. So, we use OncoEMR, and it’s structured data requires a lot of clicks in the boxes and a lot of remembrance from anybody whose touching the EMR. Anybody from the front desk to the back office to the providers. Nurses, of course, they have to do their piece.
So, it requires much longer and more work in the EMR and that is one piece that has been very overwhelming, and that cause a lot of physician burnout on our part.
The other thing is, of course, data sharing. Now that piece, we have a very good value-based care team; the head of it, Amy Ellis, and the team, the [information technology] team at Northwest Medical Specialties, has actually done a very smooth job on collecting the data and sharing it. Of course, it’s a lot of work, but I don’t think it was as burdensome as what we had gone through prior to putting all that data into the EMR.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More
